Roche: Divarasib Shows Superiority Over Approved KRAS G12C Inhibitors In Phase III NSCLC Trial
Achieves Statistically Significant Improvements In Progression-Free Survival And Overall Survival Data To Be Submitted To Health Authorities And Presented At Upcoming Medical Meeting
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.